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Abstract
Objective
To estimate the risks of incident mental health
disorders in survivors of the acute phase of covid-19.
Design
Cohort study.
Setting
US Department of Veterans Affairs.
Participants
Cohort comprising 153 848 people who survived the
first 30 days of SARS-CoV-2 infection, and two control
groups: a contemporary group (n=5 637 840) with no
evidence of SARS-CoV-2, and a historical control group
(n=5 859 251) that predated the covid-19 pandemic.
Main outcomes measures
Risks of prespecified incident mental health
outcomes, calculated as hazard ratio and absolute
risk difference per 1000 people at one year,
with corresponding 95% confidence intervals.
Predefined covariates and algorithmically selected
high dimensional covariates were used to balance
the covid-19 and control groups through inverse
weighting.
Results
The covid-19 group showed an increased risk of
incident anxiety disorders (hazard ratio 1.35 (95%
confidence interval 1.30 to 1.39); risk difference 11.06
(95% confidence interval 9.64 to 12.53) per 1000
people at one year), depressive disorders (1.39 (1.34
to 1.43); 15.12 (13.38 to 16.91) per 1000 people at
one year), stress and adjustment disorders (1.38 (1.34

What is already known on this topic
Studies limited to short follow-up (<6 months) and narrow selection of mental
health outcomes showed that people with covid-19 might be at increased risk of
anxiety and depression
A comprehensive assessment of the mental health manifestations in people with
covid-19 at one year is important

What this study adds
People with covid-19 show increased risks of incident mental health
disorders (eg, anxiety disorders, depressive disorders, stress and adjustment
disorders, opioid use disorders, other (non-opioid) substance use disorders,
neurocognitive decline, and sleep disorders) compared with contemporary
controls without SARS-CoV-2 or historical controls before the pandemic
The risks of mental health disorders were evident even among those who
were not admitted to hospital and were highest in those who were admitted to
hospital for covid-19 during the acute phase of the disease
People with covid-19 showed higher risks of mental health disorders than people
with seasonal influenza; people admitted to hospital for covid-19 showed
increased risks of mental health disorders compared with those admitted to
hospital for any other cause
the bmj | BMJ 2022;376:e068993 | doi: 10.1136/bmj-2021-068993

to 1.43); 13.29 (11.71 to 14.92) per 1000 people at
one year), and use of antidepressants (1.55 (1.50 to
1.60); 21.59 (19.63 to 23.60) per 1000 people at one
year) and benzodiazepines (1.65 (1.58 to 1.72); 10.46
(9.37 to 11.61) per 1000 people at one year). The
risk of incident opioid prescriptions also increased
(1.76 (1.71 to 1.81); 35.90 (33.61 to 38.25) per 1000
people at one year), opioid use disorders (1.34 (1.21
to 1.48); 0.96 (0.59 to 1.37) per 1000 people at one
year), and other (non-opioid) substance use disorders
(1.20 (1.15 to 1.26); 4.34 (3.22 to 5.51) per 1000
people at one year). The covid-19 group also showed
an increased risk of incident neurocognitive decline
(1.80 (1.72 to 1.89); 10.75 (9.65 to 11.91) per 1000
people at one year) and sleep disorders (1.41 (1.38 to
1.45); 23.80 (21.65 to 26.00) per 1000 people at one
year). The risk of any incident mental health diagnosis
or prescription was increased (1.60 (1.55 to 1.66);
64.38 (58.90 to 70.01) per 1000 people at one year).
The risks of examined outcomes were increased even
among people who were not admitted to hospital
and were highest among those who were admitted to
hospital during the acute phase of covid-19. Results
were consistent with those in the historical control
group. The risk of incident mental health disorders
was consistently higher in the covid-19 group in
comparisons of people with covid-19 not admitted
to hospital versus those not admitted to hospital for
seasonal influenza, admitted to hospital with covid-19
versus admitted to hospital with seasonal influenza,
and admitted to hospital with covid-19 versus
admitted to hospital for any other cause.
Conclusions
The findings suggest that people who survive the
acute phase of covid-19 are at increased risk of an
array of incident mental health disorders. Tackling
mental health disorders among survivors of covid-19
should be a priority.

Introduction
During the post-acute phase of covid-19, patients are at
increased risk of developing mental health disorders.1
2
Studies to date have been limited by narrow selection
of mental health outcomes and a maximum of six
months’ follow-up. A comprehensive assessment of the
mental health manifestations in people with covid-19
at one year has not been undertaken. Improving our
understanding of the long term risk of mental health
disorders in people with covid-19 can help guide
strategies for care during the post-acute phase.
We extracted data from the US Department of
Veterans Affairs national healthcare databases to
estimate the risks of incident mental health outcomes
in people who survived the acute phase of covid-19.
From these data we constructed a cohort of 153 848 US
1
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veterans who survived the first 30 days of SARS-CoV-2
infection and two control groups—a contemporary
group consisting of 5 637 840 users of the US
Department of Veterans Health Care System (Veterans
Health Administration) with no evidence of SARSCoV-2 infection, and a historical control (predating the
covid-19 pandemic) consisting of 5 859 251 users of
the healthcare system during 2017. We followed these
cohorts longitudinally to estimate the risks of a set of
prespecified incident mental health outcomes in the
overall cohort and according to care setting during the
acute phase of the infection—that is, whether people
were or were not admitted to hospital during the first
30 days of covid-19.

Methods
The study was conducted using data from the Veterans
Health Administration, which operates the largest
nationally integrated healthcare system in the US; it
provides healthcare to veterans discharged from the
US armed forces. The Veterans Health Administration
provides a comprehensive medical benefits package
that includes outpatient care, inpatient hospital care,
mental healthcare, prescriptions, medical equipment,
and prosthetics. The healthcare system operates 1255
healthcare facilities, including 170 medical centers
and 1074 outpatient sites.
Cohort
Those who had used the Veterans Health
Administration in 2019 (n=6 241 875) and had at least
one positive covid-19 polymerase chain reaction (PCR)
test result between 1 March 2020 and 15 January 2021
were selected into the covid-19 group (n=169 240).
From this group we then selected those who were alive
30 days after the positive test result (n=153 848) to
examine outcomes during the post-acute phase. The
start of follow-up was set as the date of the positive test
result in the covid-19 group; follow-up ended on 30
November 2021.
We then constructed a non-infected contemporary
control group from those who used the Veterans
Health Administration in 2019 (n=6 241 875). Those
alive by 1 March 2020 (n=5 961 157) and not in the
covid-19 group were selected into the non-infected
contemporary control group (n=5 807 309). To
ensure that the contemporary control group had a
similar distribution of follow-up time as the covid-19
group, we randomly assigned the start of follow-up
for participants in the contemporary control group
following the same distribution of the date of a positive
test result in the covid-19 group, so that the proportion
of participants with the start of follow-up on a certain
date was the same in both groups. Overall, 5 659 095
participants alive at the assigned start of follow-up and
5 637 840 of them alive 30 days after the start of followup were further selected as the contemporary control
group; follow-up ended on 30 November 2021.
To examine the associations between covid-19 and
mental health outcomes compared with a non-infected
control group of people who did not experience
2

the pandemic, we built a historical control group
from participants who used the Veterans Health
Administration in 2017 (n=6 461 596). Within those
who were alive on 1 March 2018 (n=6 150 654),
participants who were not in the covid-19 group were
selected into the non-infected historical control group
(n=6 008 474). To ensure that the historical control
group had a similar distribution of follow-up time as
the covid-19 group, we randomly assigned the start
of follow-up for participants in the historical control
group to have a similar distribution as the start of
follow-up minus two years (730 days) in the covid-19
group. Overall, 5 875 992 participants were alive at the
start of follow-up; 5 859 251 of them alive 30 days after
the start of follow-up and were further selected as the
historical control group. Follow-up in the historical
control group ended on 30 November 2019.
The covid-19 group was further categorized into
those who were not admitted to hospital (n=132 852)
and those who were admitted to hospital (n=20 996)
with covid-19 during the acute phase of the disease.
We constructed additional control (comparison)
groups including participants with a seasonal
influenza positive test result between 1 October 2017
and 29 February 2020 and were alive 30 days after
the positive test result (n=72 207). This cohort was
then categorized into those who were not admitted
to hospital in the first 30 days after the positive test
result (n=60 283) and those who were admitted to
hospital in the first 30 days after the positive test result
(n=11 924). Follow-up time was assigned to match
the distribution of the follow-up time in the relevant
covid-19 comparison group.
We also constructed a cohort including those who
were admitted to hospital for any cause between 1
October 2017 and 29 February 2020 and were alive 30
days after the hospital stay (n=786 676). Follow-up time
was assigned to match the distribution of the follow-up
time in the relevant covid-19 comparison group.

Data sources
Data used in this study were obtained from the
Veteran Affairs Corporate Data Warehouse.3-7 Within
this data warehouse, the patient data domain
provided demographic information; the outpatient
encounters domain and inpatient encounters domain
provided clinical information, including diagnoses
and procedures; the outpatient pharmacy and bar
code medication administration domains provided
pharmacy records; and the laboratory results domain
provided laboratory test information. Information
on covid-19 was obtained from the Veteran Affairs
covid-19 shared data resource. Additionally, as
a summary contextual measure we used the area
deprivation index—a composite measure of income,
education, employment, and housing in the
participants’ residential locations.8
Prespecified outcomes
The outcomes were prespecified based on our previous
work on the systematic characterization of the postdoi: 10.1136/bmj-2021-068993 | BMJ 2022;376:e068993 | the bmj
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acute sequelae of SARS-CoV-2 infection, and several
other studies.1 2 9-15 Outcomes based on ICD-10
codes (international classification of diseases, 10th
revision) were anxiety disorders (generalized anxiety
disorder, mixed anxiety disorder, and panic disorder),
depressive disorders (major depressive disorder—
single episode, recurrent major depressive disorder,
and suicidal ideation), stress disorders (acute stress
and adjustment disorder and post-traumatic stress
disorder), opioid use disorder, substance use disorder
(illicit drug use disorder, alcohol use disorder, and
sedative or hypnotics use disorder), neurocognitive
decline, and sleep disorders. Outcomes based on
prescription records included antidepressant drugs
(selective serotonin reuptake inhibitors, serotoninnoradrenaline (norepinephrine) reuptake inhibitors,
other antidepressants), benzodiazepines, opioids,
naloxone and naltrexone, methadone, buprenorphine,
and drugs to aid sleep. Supplementary table 1 details
the outcome definitions. Incidence of each mental
health outcome was assessed after 30 days of a positive
SARS-CoV-2 test result in those without a history of the
outcome in the two years before the start of follow-up.
We also specified three composite outcomes of any
mental health diagnosis, any mental health related
drug prescription, and any mental health diagnosis or
drug prescription, and we examined the incidence of
these composite outcomes in those without any mental
health diagnosis or drug prescription within two years
before the start of follow-up.

Covariates
In this study we used both predefined and
algorithmically selected high dimensional covariates
assessed within one year before the start of follow-up.
Predefined covariates were selected based on previous
knowledge.1 10 13-15 The predefined covariates included
age; race (white people, black people, and other); sex;
area deprivation index; body mass index; smoking
status (current, former, and never smoker); and
healthcare utilization measures, including number of
outpatient encounters, history of hospital admission,
and use of long term care. The battery of predefined
covariates also included comorbidities such as cancer,
chronic kidney disease, chronic lung disease, dementia,
diabetes mellitus, dysautonomia, hyperlipidemia,
and hypertension. Additionally, we adjusted for
estimated glomerular filtration rate and systolic and
diastolic blood pressure. Missing values (0.80% of
body mass index, 0.97% of blood pressure, and 5.39%
of estimated glomerular filtration rate in covid-19
group) were imputed based on mean predicted value
conditional on age, race, sex, and group assignment.
Continuous variables were transformed into restricted
cubic spline functions to account for potential nonlinear associations with the group assignment.
To further optimize adjustment of potential
confounders, we algorithmically selected high
dimensional covariates from several data domains,
including diagnoses, drugs, and laboratory tests.16
We classified all patient encounters, prescriptions,
the bmj | BMJ 2022;376:e068993 | doi: 10.1136/bmj-2021-068993

and laboratory data into 540 diagnostic categories,
543 drug classes, and 62 laboratory tests. We further
selected those variables that occurred in at least 100
participants within each group. The univariate relative
risk between each variable and group assignment was
then estimated; the top 100 variables with the strongest
association were then used as the high dimensional
covariates.17 The high dimensional covariates
selection process was conducted independently for
the examination of each outcome, and also conducted
independently for each comparison.

Statistical analyses
Baseline characteristics of the covid-19, contemporary,
and historical non-infected control groups are
presented as means (standard deviations) and
numbers (percentages) as appropriate. Standardized
mean differences between groups are also described.
Associations between covid-19 and incident mental
health disorders were estimated through weighted
survival analyses adjusting for both predefined and
algorithmically selected high dimensional covariates.
To examine the risk of each incident outcome, we
constructed a subcohort of participants with no history
of the outcome being examined (ie, participants with
a history of major depressive disorders were removed
from the analyses examining the risk of incident major
depressive disorders). In each subcohort, we built
logistic regressions to estimate the propensity score
of each group (covid-19, contemporary control, and
historical control) belonging to the target population of
users of the Veterans Health Administration in 2019,
utilizing both predefined and algorithmically selected
high dimensional covariates. We then computed the
inverse probability weights for each participant as the
probability of belonging to the target population divided
by the probability of being in the observed population.
To examine the success of weighting we assessed the
standardized mean differences for covariates in the
weighted population.18 Cause specific hazard models
were then used with the inverse probability weights,
and when death was considered as a competing risk.
We report two measures of risk: the adjusted hazard
ratios during follow-up and the adjusted risk difference
per 1000 people at one year based on the difference
between the estimated incidence rate in the covid-19
group and control groups at one year.
To examine the association between covid-19 and
mental health disorders by care setting of the acute
infection, we conducted analyses in the covid-19
group categorized into two mutually exclusive groups
as not admitted to hospital or admitted to hospital for
covid-19 during the acute phase of the infection (the
first 30 days after a positive test result). We estimated
propensity score and inverse probability weights
separately for each care setting. Cause specific hazard
models were then conducted in the inverse probability
weighted cohort to estimate hazard ratios, event rates,
and risk differences.
We additionally conducted several comparative
analyses: not admitted to hospital for covid-19 versus
3
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not admitted to hospital for seasonal influenza;
admitted to hospital for covid-19 versus admitted
to hospital for seasonal influenza; and admitted to
hospital for covid-19 versus admitted to hospital for
any other cause. Analyses within people admitted to
hospital were additionally adjusted for intensive care
unit admission and length of hospital stay. Admission
to hospital was defined as being admitted to hospital
for a condition related to the infection and was
ascertained in the first 30 days after the positive test
result (covid-19 or seasonal influenza). Comparisons
were conducted based on cause specific hazard model,
balancing through overlap weighting generated from
both predefined and algorithmically selected high
dimensional covariates.19
To test the robustness of our findings, we performed
four sensitivity analyses. Firstly, we expanded our
inclusion of high dimensional covariates to adjust for
the top 300 variables with the strongest association with
group assignment (instead of top 100 in the primary
analyses). Secondly, we examined the associations
without application of the high dimensional variable
selection algorithm by using only predefined covariates
to construct the inverse probability weights. Thirdly,
we alternatively applied the doubly robust approach
(in lieu of the inverse weighting approach used in the
primary analyses), where we additionally adjusted for
covariates in the weighted survival models.20 Finally,
we additionally adjusted for the number of outpatient
visits and number of hospital admissions during the
follow-up as time varying variables.
To further test the rigor of our approach, we first
tested fatigue (a cardinal feature of post-acute sequelae
of SARS-CoV-2 infection) as a positive outcome control
to assess whether our approach would reproduce
known associations. We then tested a battery of
negative outcome controls where no previous
knowledge suggests an association is expected.21 The
successful application of both positive and negative
controls might lessen concern about the presence of
spurious biases related to the cohort construction,
study design, covariate selection, analytic approach,
outcome ascertainment, residual confounding, and
other sources of latent biases.
Robust sandwich variance estimators were applied
to adjust for the variance after application of weighting.
Statistical significance was determined by a 95%
confidence interval that excluded 1 for ratios and 0 for
rates. Analyses were conducted using SAS Enterprise
Guide version 8.2 (SAS Institute, Cary, NC), and results
were visualized using R version 4.05.

Patient and public involvement
The general topic of this research was inspired by
the community of patients with long covid whose
admirable advocacy served as an inspiration to pursue
this area of research.
Results
Figure 1 shows the selection of the study cohort. The
study population comprised 153 848 participants in
4

the covid-19 group, 5 637 840 in the contemporary
control group, and 5 859 251 in the historical control
group. Median follow-up was, respectively, 377 days
(interquartile range 347-469 days), 378 (348-471)
days, and 378 (347-470) days. Person years of followup were 172 091 in the covid-19 group, 6 317 461 in
the contemporary control group, and 6 563 236 in the
historical control group, corresponding to a total of
13 052 788 person years of follow-up. Table 1 shows
the demographic and health characteristics of the
three study groups after weighting, and supplementary
table S2 shows the data before weighting.

Risks of incident mental health disorders
Covid-19 group versus contemporary control group
Assessment of standardized mean differences after
inverse probability weighting suggested that the
covariates were well balanced between the covid-19
group and contemporary control group (supplementary
figure S1). Figure 2 and supplementary table S3
provide the risks of incident mental health disorders
in these groups.
Anxiety, depression, and stress disorders—people
who survived the first 30 days of covid-19 showed an
increased risk of incident anxiety disorders (hazard
ratio 1.35 (95% confidence interval 1.30 to 1.39);
risk difference 11.06 (95% confidence interval 9.64
to 12.53) per 1000 people at one year), depressive
disorders (1.39 (1.34 to 1.43); 15.12 (13.38 to 16.91)
per 1000 people at one year), and stress and adjustment
disorders (1.38 (1.34 to 1.43); 13.29 (11.71 to 14.92)
per 1000 people at one year). This was coupled with an
increased risk of incident use of antidepressants (1.55
(1.50 to 1.60); 21.59 (19.63 to 23.60) per 1000 people
at one year) and benzodiazepines (1.65 (1.58 to 1.72);
10.46 (9.37 to 11.61) per 1000 people at one year).
Opioids—The risk of incident opioid prescriptions
was increased (1.76 (1.71 to 1.81); 35.90 (33.61 to
38.25) per 1000 people at one year). This was coupled
with an increased risk of opioid use disorders (1.34
(1.21 to 1.48); 0.96 (0.59 to 1.37) per 1000 people at
one year) and incident use of naloxone or naltrexone
(1.23 (1.18 to 1.29); 3.08 (2.32 to 3.86) per 1000
people at one year), buprenorphine (1.34 (1.12 to
1.62); 0.45 (0.15 to 0.80) per 1000 people at one
year), and methadone (1.94 (1.47 to 2.56); 0.27 (0.14
to 0.46) per 1000 people at one year).
Any substance use disorders—These included
increased risk of illicit drug use (1.24 (1.16 to 1.32);
2.12 (1.42 to 2.87) per 1000 people at one year),
alcohol use disorders (1.29 (1.22 to 1.35); 4.60 (3.61
to 5.65) per 1000 people at one year), and sedative or
hypnotic use disorders (1.40 (1.14 to 1.72); 0.28 (0.10
to 0.51) per 1000 people at one year). The risk of any
(non-opioid) substance use disorders was 1.20 (1.15 to
1.26); 4.34 (3.22 to 5.51) per 1000 people at one year.
Neurocognitive decline—The risk of incident
neurocognitive decline was increased (1.80 (1.72 to
1.89); 10.75 (9.65 to 11.91) per 1000 people at one year).
Sleep—The risk of incident sleep disorders was
increased (1.41 (1.38 to 1.45); 23.80 (21.65 to 26.00)
doi: 10.1136/bmj-2021-068993 | BMJ 2022;376:e068993 | the bmj
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Contemporary control group

Covid-19 group

Historical control group

6 241 875
Used VHA in 2019

6 241 875
Used VHA in 2019

6 461 596
Used VHA in 2017

5 961 157
Alive by 1 March 2020

5 807 309
Not part of covid-19 group

6 150 654
Alive by 1 March 2018
169 240
First covid-19 positive test
result between 1 March 2020
and 15 January 2021

6 008 474
Not part of covid-19 group

5 659 095
Alive at assigned
start of follow-up

5 637 840
Alive 30 days aer
assigned start of follow-up

5 875 992
Alive at assigned
start of follow-up

153 848
Alive 30 days aer covid-19
positive test result

Covid-19 v
contemporary control

5 605 762
Not admitted
to hospital

132 852
Not admitted
to hospital

Comparison by care setting of the acute
phase of covid-19 v contemporary control

5 859 251
Alive 30 days aer
assigned start of follow-up

Covid-19 v
historical control

20 996
Admitted
to hospital

5 809 064
Not admitted
to hospital

Comparison by care setting of the acute
phase of covid-19 v historical control

Fig 1 | Flowchart showing selection of cohort. VHA=Veterans Health Administration

per 1000 people at one year) as was the risk of incident
use of sleep medications (1.63 (1.58 to 1.67); 25.87
(24.01 to 27.78) per 1000 people at one year).
Composite endpoints—The risk of any incident
mental health diagnosis was 1.46 (1.40 to 1.52); 36.48
(31.93 to 41.19) per 1000 people at one year), any
incident mental health related drug prescription was
1.86 (1.78 to 1.95); 47.60 (43.26 to 52.12) per 1000
people at one year), and any incident mental health
diagnosis or prescription was 1.60 (1.55 to 1.66);
64.38 (58.90 to 70.01) per 1000 people at one year; fig
3). Figure 4 presents the adjusted survival probabilities
of the composite endpoints across time.

Covid-19 group v contemporary control group by
care setting

The risks of incident mental health disorders
were compared between the covid-19 group and
contemporary control group by care setting of the acute
phase (first 30 days) of covid-19. Within the covid-19
group, 132 852 people were not admitted to hospital
and 20 996 were admitted to hospital for covid-19.
Supplementary table S4 shows the demographic
and health characteristics of these groups before
the bmj | BMJ 2022;376:e068993 | doi: 10.1136/bmj-2021-068993

weighting, and supplementary table S5 after weighting.
Standardized mean differences suggested that
covariates were well balanced (supplementary figure
S2). Compared with the contemporary control group,
the risks of the prespecified mental health outcomes
in the covid-19 group were evident in those who were
not admitted to hospital and were highest in those who
were admitted to hospital during the acute phase of the
disease (fig 5, fig 6, fig 7, and supplementary table S6).
Among people with covid-19, a pairwise comparison of
those who were not admitted to hospital versus those
who were admitted to hospital for covid-19 during
the acute phase of the disease suggested that those
who were admitted to hospital showed a higher risk
of incident mental health outcomes (supplementary
table S7).

Covid-19 group v historical control group
Supplementary table S2 shows the demographic
and health characteristics of the covid-19 group and
historical control group before weighting, and table
1 after weighting; the characteristics of the groups
were balanced after weighting (supplementary
figure S3). The results suggested increased risks
5
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Table 1 | Baseline demographic and health characteristics of covid-19, contemporary control, and historical control groups after weighting
Characteristics
Mean (SD) age (years)
Race:
White
Black
Other
Sex:
Men
Women
BMI category:
Underweight or normal
Overweight
Obese
Smoking status:
Never
Former
Current
Mean (SD) area deprivation index†
Clinical characteristics
Outpatient encounter‡:
0 or 1
2
≥3
Long term care
Mean (SD) eGFR (ml/min/1.73m2)
Mean (SD) blood pressure (mm Hg):
Systolic
Diastolic
Cancer
Cerebrovascular disease
Cardiovascular disease
Chronic kidney disease
Chronic lung disease
Diabetes mellitus type 2
Rheumatoid arthritis

Covid-19 (n=153 848)
63.06 (16.18)

Contemporary control
(n=5 637 840)
63.40 (16.22)

Historical control
(n=5 859 251)
63.32 (16.30)

Absolute standardized
difference: covid-19 and
contemporary control*
0.02

Absolute standardized
difference: covid-19
and historical control*
0.02

116 729 (75.87)
29 708 (19.31)
7412 (4.82)

4 320 333 (76.63)
1 050 386 (18.63)
267 121 (4.74)

4 486 253 (76.57)
1 093 102 (18.66)
279 838 (4.78)

0.02
0.02
0.00

0.02
0.02
0.00

137 265 (89.22)
16 583 (10.78)

5 089 729 (90.28)
548 111 (9.72)

5 286 158 (90.22)
573 093 (9.78)

0.03
0.03

0.03
0.03

29 611 (19.25)
54 742 (35.58)
69 495 (45.17)

1 091 937 (19.37)
2 051 835 (36.39)
2 494 011 (44.24)

1 134 761 (19.37)
2 121 869 (36.21)
2 602 562 (44.42)

0.00
0.02
0.02

0.00
0.01
0.02

62 570 (40.67)
57 016 (37.06)
34 260 (22.27)
55.09 (18.96)

2 400 310 (42.58)
2 037 233 (36.14)
1 200 296 (21.29)
54.67 (19.03)

2 498 736 (42.65)
2 112 201 (36.05)
1 248 313 (21.31)
54.65 (19.03)

0.04
0.02
0.02
0.02

0.04
0.02
0.02
0.02

60 471 (39.31)
42 513 (27.63)
50 864 (33.06)
1882 (1.22)
78.83 (21.08)

2 414 912 (42.83)
1 620 202 (28.74)
1 602 725 (28.43)
38 676 (0.69)
78.67 (20.60)

2 508 580 (42.81)
1 661 566 (28.36)
1 689 105 (28.83)
41 483 (0.71)
78.73 (20.62)

0.07
0.02
0.10
0.06
0.01

0.07
0.02
0.09
0.05
0.00

132.47 (12.36)
77.77 (7.59)
10 369 (6.74)
7719 (5.02)
21 671 (14.09)
26 651 (17.32)
19 662 (12.78)
36 850 (23.95)
1502 (0.98)

132.65 (12.28)
77.79 (7.53)
348 024 (6.17)
246 599 (4.37)
717 528 (12.73)
943 774 (16.74)
616 498 (10.94)
1 286 048 (22.81)
49 669 (0.88)

132.61 (12.33)
77.80 (7.56)
361 516 (6.17)
257 866 (4.4)
745 531 (12.72)
977 675 (16.69)
641 061 (10.94)
1 335 733 (22.80)
51 679 (0.88)

0.01
0.00
0.02
0.03
0.04
0.02
0.06
0.03
0.01

0.01
0.00
0.02
0.03
0.04
0.02
0.06
0.03
0.01

SD=standard deviation; BMI=body mass index; eGFR=estimated glomerular filtration rate.
*Value ≤0.10 is considered good balance.
†Measure of socioeconomic disadvantage (from 0 to 100 representing low to high disadvantage).
‡Data collected within one year of cohort enrollment.

of the prespecified mental health outcomes in the
covid-19 group compared with historical control
group (supplementary table S8 and supplementary
figure S4-S6)—and were consistent with those of the
covid-19 group compared with contemporary control
group.
Analyses were also performed by care setting of
the acute phase of infection. Supplementary table S9
presents the demographic and health characteristics
of the covid-19 and historical control groups before
weighting, and supplementary table S10 after
weighting. Characteristics of the two groups were
balanced after weighting (supplementary figure S7).
The risks of the prespecified mental health outcomes
showed an increase according to the intensity of care
during the acute phase of the infection—and were
consistent with results for the covid-19 group compared
with contemporary control group (supplementary
table S11 and figures S8-S10).

Covid-19 v seasonal influenza
To better understand the increased risk of incident
mental health outcomes in people with covid-19, the
risk of incident composite mental health outcomes
6

was compared between the covid-19 group and a
group with seasonal influenza (n=72 207), a well
characterized respiratory viral infection. In the
seasonal influenza group, 60 283 were not admitted
to hospital and 11 924 were admitted to hospital.
This analysis was conducted in those not admitted to
hospital, and, separately, in those admitted to hospital
for covid-19 or for seasonal influenza (additionally
adjusting for intensive care admission and length of
stay during the hospital admission). Compared with
seasonal influenza, covid-19 was associated with
increased risk of mental health outcomes in people
who both were and were not admitted to hospital (fig
8, supplementary table S12).

Hospital admissions for covid-19 v for any other
cause
To gain a better understanding of whether the
increased risk of incident mental health outcomes in
people admitted to hospital for covid-19 was driven
by the hospital admission itself, the risks of incident
composite mental health outcomes were compared
between those admitted to hospital for covid-19 and
those admitted for any other cause (n=786 676),
doi: 10.1136/bmj-2021-068993 | BMJ 2022;376:e068993 | the bmj
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Outcome

Anxiety disorders
Generalized anxiety disorder
Mixed anxiety disorder
Panic disorder
Depressive disorders
MDD - single episode
MDD - recurrent
Suicidal ideation
Stress and adjustment disorders
Acute stress and adjustment disorder
PTSD
Antidepressants
SSRI
SNRI
Other antidepressants
Benzodiazepines
Opioids
Opioid prescription
Opioid use disorder
Naloxone or naltrexone
Methadone
Buprenorphine
Substance use disorders
Any substance use disorder
Illicit drug disorder
Alcohol use disorder
Sedative or hypnotics use disorder
Neurocognitive decline
Sleep
Sleep disorders
Sleep medications

Risk difference per 1000
Risk difference per 1000
people at one year (95% CI) people at one year (95% CI)

Hazard ratio
(95% CI)

Hazard ratio
(95% CI)
1.35 (1.30 to 1.39)
1.34 (1.30 to 1.39)
1.41 (1.30 to 1.54)
1.28 (1.17 to 1.41)
1.39 (1.34 to 1.43)
1.42 (1.37 to 1.47)
1.29 (1.24 to 1.34)
1.46 (1.35 to 1.57)
1.38 (1.34 to 1.43)
1.48 (1.42 to 1.54)
1.30 (1.24 to 1.36)
1.55 (1.50 to 1.60)
1.54 (1.49 to 1.60)
1.22 (1.17 to 1.28)
1.56 (1.48 to 1.64)
1.65 (1.58 to 1.72)

11.06 (9.64 to 12.53)
10.56 (9.18 to 11.99)
1.66 (1.21 to 2.15)
0.84 (0.49 to 1.22)
15.12 (13.38 to 16.91)
12.53 (11.15 to 13.95)
7.86 (6.58 to 9.18)
2.25 (1.73 to 2.81)
13.29 (11.71 to 14.92)
8.05 (7.08 to 9.07)
6.60 (5.39 to 7.85)
21.59 (19.63 to 23.60)
17.13 (15.47 to 18.84)
3.23 (2.45 to 4.06)
5.98 (5.14 to 6.86)
10.46 (9.37 to 11.61)

1.76 (1.71 to 1.81)
1.34 (1.21 to 1.48)
1.23 (1.18 to 1.29)
1.94 (1.47 to 2.56)
1.34 (1.12 to 1.62)

35.90 (33.61 to 38.25)
0.96 (0.59 to 1.37)
3.08 (2.32 to 3.86)
0.27 (0.14 to 0.46)
0.45 (0.15 to 0.80)

1.20 (1.15 to 1.26)
1.24 (1.16 to 1.32)
1.29 (1.22 to 1.35)
1.40 (1.14 to 1.72)
1.80 (1.72 to 1.89)

4.34 (3.22 to 5.51)
2.12 (1.42 to 2.87)
4.60 (3.61 to 5.65)
0.28 (0.10 to 0.51)
10.75 (9.65 to 11.91)

1.41 (1.38 to 1.45)
1.63 (1.58 to 1.67)

23.80 (21.65 to 26.00)
25.87 (24.01 to 27.78)
0 1

2

0

3

10

20

30

40

Fig 2 | Risks of incident mental health outcomes in covid-19 group during the post-acute phase compared with contemporary control group.
Outcomes were ascertained 30 days after the initial SARS-CoV-2 positive test result until the end of follow-up. Hazard ratios are estimated through
the follow-up and adjusted for age, race, sex, area deprivation index, body mass index, smoking status, number of outpatient encounters, history
of hospital admission, use of long term care, cancer, chronic kidney disease, chronic lung disease, dementia, diabetes mellitus, dysautonomia,
hyperlipidemia, hypertension, estimated glomerular filtration rate, systolic and diastolic blood pressure, and algorithmically selected high
dimensional covariates. Risk differences are estimated at one year. MDD=major depressive disorder; PTSD=post-traumatic stress disorder;
SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin-noradrenaline (norepinephrine) reuptake inhibitor
Outcome

Hazard ratio
(95% CI)

Hazard ratio
(95% CI)

Risk difference per 1000
Risk difference per 1000
people at one year (95% CI) people at one year (95% CI)

1.46 (1.40 to 1.52)
Any mental health diagnosis
Any mental health related drug prescription 1.86 (1.78 to 1.95)
Any mental health diagnosis or prescription 1.60 (1.55 to 1.66)

36.48 (31.93 to 41.19)
47.60 (43.26 to 52.12)
64.38 (58.90 to 70.01)
0 1.0

1.5

2.0

0

20

40

60

80

Fig 3 | Risks of incident composite mental health outcomes in covid-19 group compared with contemporary control group. Composite outcomes
consisted of any mental health related drug prescription, any mental health diagnosis, and any mental health diagnosis or prescription. Outcomes
were ascertained 30 days after the initial SARS-CoV-2 positive test result until end of follow-up. Hazard ratios are estimated through the follow-up
and adjusted for age, race, sex, area deprivation index, body mass index, smoking status, number of outpatient encounters, history of hospital
admission, use of long term care, cancer, chronic kidney disease, chronic lung disease, dementia, diabetes mellitus, dysautonomia, hyperlipidemia,
hypertension, estimated glomerular filtration rate, systolic and diastolic blood pressure, and algorithmically selected high dimensional covariates.
Risk differences are estimated at one year
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Survival probability

1.00

Any mental health diagnosis

0.95
0.90
0.85

Contemporary control
Covid-19

0.80
0.75

Contemporary control
2 173 967
2 075 397

Survival probability

Covid-19
34 339

1.00

31 181

1 988 590

807 023

29 378

11 209

Any mental health related drug prescription

0.95
0.90
0.85
0.80
0.75

Contemporary control
2 173 967
2 101 511

Survival probability

Covid-19
34 339

1.00

31 463

2 033 790

832 375

29 934

11 545

Any mental health diagnosis or prescription

0.95
0.90
0.85

Sensitivity analyses
Multiple sensitivity analyses were conducted
to investigate the robustness of the results. The
associations were examined between covid-19 and
risks of any mental health related drug prescription,
any mental health diagnosis, and any mental health
diagnosis or drug prescription; the sensitivity analyses
compared the covid-19 group with the contemporary
control group and with the historical control group,
and additionally compared the covid-19 group across
care settings versus both control groups. Firstly, in
constructing the inverse probability weighting, the
number of algorithmically selected covariates and
predefined covariates were expanded to 300 instead
of 100. Secondly, only predefined covariates were used
to construct the inverse probability weighting. Thirdly,
the doubly robust method was used as an alternative
modelling approach to the inverse probability
weighting method used in the primary analysis.
Lastly, the numbers of outpatient visits and hospital
admissions during follow-up were additionally
adjusted for as time varying variables. The results
were found to be robust in these sensitivity analyses
(supplementary tables S13 and S14).
Positive and negative outcome controls
To test whether the study’s approach would
reproduce established knowledge, the association
between covid-19 and the risk of fatigue (a cardinal
manifestation of post-acute covid-19) as a positive
outcome control was examined. The results suggested
that covid-19 was associated with increased risk of
fatigue (supplementary table S15).
The association was then tested between covid-19
and four negative outcome controls (lichen planus,
lichen simplex chronicus, melanoma in situ,
and allergic eczema) where an association is not
known. Consistent with a priori expectations, no
statistically significant association was found between
covid-19 and any of the negative outcome controls
(supplementary table S15).

0.80
0.75
0

60

120

Contemporary control
2 173 967
2 046 083
Covid-19
34 339

29 809

180

240

300

360
Days

1 935 858

777 377

27 356

10 187

Fig 4 | Survival probability of incident composite mental health outcomes in covid-19
group compared with contemporary control group. Outcomes were ascertained 30 days
after the initial SARS-CoV-2 positive test result until end of follow-up. Shaded areas
are 95% confidence intervals. Numbers of participants at risk across groups are also
presented

additionally adjusting for intensive care admission
and length of stay during the hospital admission.
People admitted to hospital for covid-19 showed a
higher risk of incident mental health outcomes than
people admitted to hospital for any other cause (fig 8,
supplementary table S12).
8

Discussion
In this study totaling 13 052 788 person years of
follow-up of 153 848 people with covid-19, 5 637 840
people in the contemporary control group, and
5 859 251 people in the historical control group, we
found that beyond the first 30 days of a positive test
result for SARS-CoV-2 infection, people with covid-19
show an increased risk of incident mental health
disorders, including anxiety disorders, depressive
disorders, stress and adjustment disorders, opioid use
disorder, other (non-opioid) substance use disorders,
neurocognitive decline, and sleep disorders. The risks
were evident even among those who were not admitted
to hospital during the acute phase of covid-19—this
group represents most people with covid-19; the risks
were highest in those who were admitted to hospital
during the acute phase of the disease. The results
were consistent when compared with a contemporary
control group without covid-19 and a historical control
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Outcome

Hazard ratio
(95% CI)

Anxiety disorders
Generalized anxiety disorder
Mixed anxiety disorder
Panic disorder
Depressive disorders
MDD - single episode
MDD - recurrent
Suicidal ideation
Stress and adjustment disorders
Acute stress and adjustment disorder
PTSD
Antidepressants
SSRI
SNRI
Other antidepressants
Benzodiazepines

Hazard ratio
(95% CI)

Risk difference per 1000
Risk difference per 1000
people at one year (95% CI) people at one year (95% CI)

1.69 (1.64 to 1.74)
2.34 (2.10 to 2.62)
1.68 (1.63 to 1.74)
2.28 (2.04 to 2.56)
1.76 (1.64 to 1.90)
2.56 (2.00 to 3.26)
1.64 (1.51 to 1.79)
2.52 (1.85 to 3.42)
1.77 (1.72 to 1.83)
2.43 (2.17 to 2.73)
1.87 (1.81 to 1.93)
2.64 (2.38 to 2.94)
1.60 (1.54 to 1.66)
1.91 (1.67 to 2.19)
3.14 (2.94 to 3.34)
4.26 (3.37 to 5.39)
1.74 (1.68 to 1.80)
2.13 (1.90 to 2.40)
1.89 (1.82 to 1.96)
2.26 (2.00 to 2.55)
1.61 (1.54 to 1.68)
1.93 (1.65 to 2.25)
2.04 (1.97 to 2.10)
3.05 (2.76 to 3.36)
2.02 (1.96 to 2.09)
2.90 (2.61 to 3.22)
1.56 (1.49 to 1.63)
1.84 (1.57 to 2.15)
2.13 (2.04 to 2.24)
3.71 (3.19 to 4.33)
2.62 (2.52 to 2.72)
4.41 (3.98 to 4.88)

21.73 (20.08 to 23.42)
41.96 (34.48 to 50.23)
20.73 (19.14 to 22.37)
38.63 (31.47 to 46.59)
3.07 (2.57 to 3.60)
6.25 (4.03 to 9.08)
1.87 (1.47 to 2.30)
4.39 (2.47 to 6.99)
30.45 (28.28 to 32.69)
55.75 (45.76 to 66.83)
25.91 (24.25 to 27.63)
48.37 (40.76 to 56.75)
16.44 (14.86 to 18.08)
24.76 (18.23 to 32.19)
10.44 (9.50 to 11.44)
15.87 (11.55 to 21.32)
25.40 (23.48 to 27.38)
38.76 (30.97 to 47.44)
14.78 (13.62 to 15.99)
20.91 (16.66 to 25.69)
13.38 (11.90 to 14.92)
20.43 (14.34 to 27.50)
40.70 (38.29 to 43.18)
78.74 (68.13 to 90.31)
32.04 (30.04 to 34.10)
58.63 (49.88 to 68.25)
8.04 (7.05 to 9.07)
12.10 (8.26 to 16.56)
12.01 (10.98 to 13.10)
28.52 (23.06 to 34.84)
25.71 (24.21 to 27.25)
53.29 (46.76 to 60.47)

2.39 (2.33 to 2.45)
4.07 (3.79 to 4.38)
2.65 (2.42 to 2.91)
3.21 (2.48 to 4.16)
2.06 (1.98 to 2.16)
2.43 (2.05 to 2.88)
4.51 (3.54 to 5.75)
3.71 (2.48 to 5.54)
2.41 (2.12 to 2.75)
3.97 (2.35 to 6.70)

64.07 (61.43 to 66.77)
135.91 (124.17 to 148.35)
4.67 (4.01 to 5.39)
6.23 (4.16 to 8.90)
13.80 (12.67 to 14.98)
18.51 (13.68 to 24.21)
1.03 (0.74 to 1.39)
0.79 (0.43 to 1.33)
1.77 (1.39 to 2.19)
3.71 (1.69 to 7.11)

1.87 (1.79 to 1.95)
2.21 (1.90 to 2.59)
2.26 (2.13 to 2.40)
2.73 (2.23 to 3.34)
1.98 (1.89 to 2.08)
2.59 (2.15 to 3.12)
3.57 (3.05 to 4.18)
4.13 (2.54 to 6.70)
2.28 (2.18 to 2.38)
4.49 (4.00 to 5.03)

18.69 (16.99 to 20.47)
26.09 (19.31 to 33.96)
11.44 (10.27 to 12.67)
15.64 (11.15 to 21.10)
15.70 (14.23 to 17.24)
25.29 (18.33 to 33.60)
1.81 (1.45 to 2.24)
2.21 (1.09 to 4.02)
17.22 (15.87 to 18.62)
46.34 (40.01 to 53.40)

1.68 (1.63 to 1.72)
2.50 (2.28 to 2.74)
2.46 (2.40 to 2.53)
4.20 (3.88 to 4.54)

38.47 (36.10 to 40.90)
83.33 (71.70 to 95.90)
59.29 (56.75 to 61.90)
124.91 (113.29 to 137.30)

Opioids
Opioid prescription
Opioid use disorder
Naloxone or naltrexone
Methadone
Buprenorphine
Substance use disorders
Any substance use disorder
Illicit drug disorder
Alcohol use disorder
Sedative or hypnotics use disorder
Neurocognitive decline
Sleep
Sleep disorders
Sleep medications

Not admitted to hospital

Admitted to hospital

01

2

4

6 8

0

50

100

150

Fig 5 | Risks of incident mental health outcomes in covid-19 group compared with contemporary control group by care setting. Outcomes were
ascertained 30 days after the initial SARS-CoV-2 positive test result until end of follow-up. Hazard ratios are estimated through the follow-up
and adjusted for age, race, sex, area deprivation index, body mass index, smoking status, number of outpatient encounters, history of hospital
admission, use of long term care, cancer, chronic kidney disease, chronic lung disease, dementia, diabetes mellitus, dysautonomia, hyperlipidemia,
hypertension, estimated glomerular filtration rate, systolic and diastolic blood pressure, and algorithmically selected high dimensional covariates.
Risk differences are estimated at one year. MDD=major depressive disorder; PTSD=post-traumatic stress disorder; SSRI=selective serotonin
reuptake inhibitor; SNRI=serotonin and noradrenaline (norepinephrine) reuptake inhibitor
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Hazard ratio
(95% CI)

Hazard ratio
(95% CI)

Outcome

Risk difference per 1000
Risk difference per 1000
people at one year (95% CI) people at one year (95% CI)

1.40 (1.35 to 1.46)
3.43 (3.02 to 3.89)
Any mental health related drug prescription 1.66 (1.60 to 1.74)
5.02 (4.46 to 5.65)
Any mental health diagnosis or prescription 1.50 (1.45 to 1.55)
3.85 (3.47 to 4.27)

31.89 (27.60 to 36.33)
177.34 (150.29 to 206.87)
37.03 (33.22 to 40.99)
202.86 (177.45 to 230.45)
53.52 (48.52 to 58.66)
265.84 (235.79 to 297.53)

Any mental health diagnosis

Not admitted to hospital

Admitted to hospital
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Fig 6 | Risks of incident composite mental health outcomes in covid-19 group compared with contemporary control group by care setting. Outcomes
were ascertained 30 days after the initial SARS-CoV-2 positive test result until end of follow-up. Hazard ratios are estimated through the follow-up
and adjusted for age, race, sex, area deprivation index, body mass index, smoking status, number of outpatient encounters, history of hospital
admission, use of long term care, cancer, chronic kidney disease, chronic lung disease, dementia, diabetes mellitus, dysautonomia, hyperlipidemia,
hypertension, estimated glomerular filtration rate, systolic and diastolic blood pressure, and algorithmically selected high dimensional covariates.
Risk differences are estimated at one year

group that predated the pandemic. The risk of incident
mental health disorders was consistently higher
in the covid-19 group in comparisons of those not
admitted to hospital for covid-19 versus not admitted
to hospital for seasonal influenza, admitted to hospital
for covid-19 versus admitted to hospital for seasonal
influenza, and admitted to hospital for covid-19 versus
admitted to hospital for any other cause. The findings
were robust to challenge in multiple sensitivity
analyses. Evaluation of positive and negative outcome
controls yielded results consistent with expectations.
Taken together, the findings suggest important risks of
mental health disorders among people who survive the
acute phase of covid-19.

Findings in relation to other studies
We evaluated the risk of mental health disorders in
people with covid-19 compared with a contemporary
control group that experienced the same pandemic
related factors (eg, economic, social, environmental
stressors) and a historical control group that predated
the pandemic, which represented a baseline for people
unaffected by the pandemic. Despite evidence showing
that the burden of mental health disorders might have
increased among the general population during the
covid-19 pandemic,22 23 our results suggested that
people with covid-19 are at even higher risk of incident
mental health disorders than their contemporaries
without covid-19; the risk was also evident in
comparisons with the historical control group. Taken
together, the findings suggest enhanced vulnerability
to these outcomes in people with covid-19.
We also compared the risk of mental health disorders
in people with covid-19 versus seasonal influenza,
a well characterized respiratory viral infection, and
showed consistently increased risks associated with
covid-19. This comparative assessment could help
to improve our understanding of the features that
differentiate post-acute covid-19 from a post-influenza
viral syndrome. Furthermore, our comparative
evaluation showing increased risk of mental health
outcomes in people admitted to hospital for covid-19
10

versus those admitted to hospital for seasonal
influenza and, separately, those admitted to hospital
for any cause helps to disentangle the effect of hospital
admission from that of covid-19 and further supports
the association between covid-19 and adverse mental
health outcomes.
Our findings show an increased risk of mental health
disorders in people with covid-19. Evidence also
suggests that people with mental health disorders are
at increased risk of becoming infected with SARS-CoV-2
and having serious outcomes.24 25 This likely suggests
the putative existence of a bidirectional connection
in that mental health disorders might predispose
someone to covid-19 and that covid-19 itself might
lead to adverse mental health manifestations. A better
understanding of the interaction of mental health
disorders both as risk for and sequela of covid-19 is
needed.
Given the large and growing number of people
with covid-19 (to date >70 million people in the US,
>15 million people in the UK, and about 350 million
people globally), the absolute risks of incident mental
health disorders might translate into large numbers
of potentially affected people around the world. Our
results should be used to promote awareness of the
increased risk of mental health disorders among
survivors of acute covid-19 and call for the integration
of mental healthcare as a core component of post-acute
covid-19 care strategies. International bodies, national
governments, and health systems must develop and
implement strategies for early identification and
treatment of affected individuals.
The mechanism or mechanisms of the increased
risks of mental health disorders in people with covid-19
are not entirely clear. Several putative mechanisms
are under examination, including peripheral T
cell infiltration of brain parenchyma, dysregulated
microglia and astrocytes, and disturbances in synaptic
signaling of upper layer excitatory neurons—all these
features generally overlap with disease phenotypes
of genetic variants associated with impaired
cognition, depression, and other neuropsychiatric
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Survival probability

1.00

disorders.26 Other likely mechanisms include a
potential role of angiotensin converting enzyme 2
mediated neuroinflammation, and the indirect effect
of a dysregulated immune response on the central
nervous system.26 Non-biologic mechanisms (eg,
changes in employment, financial problems, social
isolation, trauma, grief, and changes in diet and
physical activity), which could have differentially
impacted people with covid-19 compared with their
contemporaries, might also have contributed to the
increased burden of mental health disorders in people
with covid-19.27-33
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Fig 7 | Survival probability of incident composite mental health outcomes in covid-19
group compared with contemporary control group by care setting. Outcomes were
ascertained 30 days after the initial SARS-CoV-2 positive test result until end of followup. Shaded areas are 95% confidence intervals. Numbers of participants at risk across
groups are also presented
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Strengths and limitations of this study
Our study has several strengths. We selected a large
national cohort of people with covid-19 to estimate
risks of a comprehensive set of prespecified incident
mental health outcomes compared with two controls
(a contemporary group with no evidence of SARSCoV-2 infection and a historical group that predated
the pandemic). In the covid-19 group we provided risk
estimates for those who were and were not admitted
to hospital—facilitating a better understanding of the
magnitude of risk in these populations. We compared
the risk of mental health outcomes in people with
covid-19 versus seasonal influenza and separately for
people admitted to hospital for covid-19 compared
with those admitted to hospital for any other cause.
We used advanced statistical methodologies and
adjusted through inverse probability weighting for
a battery of predefined covariates selected based on
previous knowledge and 100 algorithmically selected
covariates from high dimensional data domains,
including diagnostic codes, prescription records, and
laboratory test results. We scrutinized our results in
multiple sensitivity analyses and applied positive
and negative outcome controls to evaluate whether
our approach would produce results consistent with
pretest expectations.
Our study also has several limitations. The
demographic composition of the cohort (mostly older
white men) might limit the generalizability of study
results. We used the vast national electronic healthcare
databases of the US Department of Veterans Affairs to
select our cohorts, and although we used validated
outcome definitions (including diagnostic codes
and prescription records) and advanced statistical
methodologies to balance the study arms for a battery
of predefined and algorithmically selected high
dimensional variables across several data domains, we
cannot completely rule out misclassification bias and
residual confounding. We categorized the covid-19
group into those who were and those who were not
admitted to hospital for covid-19 during the first 30
days of a positive SARS-CoV-2 test result; our approach
does not account for the spectrum of disease severity
among participants who were not admitted to hospital
(eg, with or without symptoms of covid-19). We did not
examine the severity of the mental health outcomes.
Although we took care to balance the study groups by
health resource utilization at baseline and conducted
11
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Covid-19 v seasonal inﬂuenza:
hospital admission
Hazard ratio (95% CI)

Covid-19 v seasonal inﬂuenza:
no hospital admission
Hazard ratio (95% CI)

Outcome

Anxiety disorders
Depressive disorders
Stress and adjustment disorders
Antidepressants
Any substance use disorder
Any mental health diagnosis
Any mental health related drug
prescription
Any mental health diagnosis or
prescription

Covid-19 v other causes:
hospital admission
Hazard ratio (95% CI)

1.44 (1.22 to 1.71)
1.32 (1.12 to 1.56)
1.51 (1.27 to 1.80)
1.42 (1.20 to 1.67)
1.26 (1.02 to 1.57)
1.44 (1.27 to 1.64)
1.29 (1.13 to 1.48)

1.34 (1.13 to 1.59)
1.24 (1.06 to 1.47)
1.41 (1.17 to 1.70)
1.56 (1.35 to 1.81)
1.12 (1.02 to 1.23)
1.43 (1.24 to 1.65)
1.39 (1.21 to 1.59)

1.63 (1.48 to 1.80)
1.42 (1.29 to 1.57)
1.36 (1.22 to 1.52)
1.92 (1.76 to 2.09)
1.18 (1.03 to 1.36)
1.62 (1.48 to 1.76)
1.89 (1.74 to 2.05)

1.27 (1.12 to 1.45)

1.45 (1.22 to 1.71)

1.86 (1.68 to 2.05)
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Fig 8 | Risks of incident composite mental health outcomes in people by covid-19 and seasonal influenza status and care setting. Outcomes were
ascertained 30 days after enrollment of the cohort until end of follow-up. Hazard ratios adjusted for age, race, sex, area deprivation index, body
mass index, smoking status, number of outpatient encounters, history of hospital admission, use of long term care, cancer, chronic kidney disease,
chronic lung disease, dementia, diabetes mellitus, dysautonomia, hyperlipidemia, hypertension, estimated glomerular filtration rate, systolic and
diastolic blood pressure, and algorithmically selected high dimensional covariates

sensitivity analyses to adjust for time varying health
resource utilization during follow-up, we cannot
completely rule out the possibility that increased
attention to people with covid-19 might have resulted
in greater ascertainment of mental health conditions
compared with both the contemporary and historical
control groups. As the pandemic continues to evolve,
new variants of the virus emerge, treatment strategies
of acute covid-19 improve, and vaccine uptake
increases, it is likely that the epidemiology of mental
health outcomes in the post-acute phase of covid-19
might also vary over time.27
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Conclusions
Using a large national cohort of people with covid-19
and contemporary and historical controls, we found
that the risks of incident mental health disorders are
substantial in people with covid-19 and span several
disorder categories, including anxiety, depression,
stress and adjustment disorders, opioid and other
substance use disorders, cognitive decline, and sleep
disorders. The risks were evident even among those
with covid-19 who did not require hospital admission.
Tackling mental health disorders among survivors of
covid-19 should be a priority.
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